BeyondSpring announced that China has designated Plinabulin a 2017 National Science and Technology Major Project. The designation implies speeded-up regulatory review and priority approval status in China. Plinabulin is currently being tested in a global Phase III clinical trial (with a large China arm) in patients with non-small cell lung cancer (NSCLC) and Phase II/III clinical program to prevent chemotherapy-induced neutropenia (CIN). BeyondSpring is a virtual company headquartered in New York City and a strong connection to China.
Source: China Biotoday